Medication info

Nexrica Capsule 50 mg (Pregabalin)

Prescription medicationHard capsuleOralExpired
Ingredient · strength
Pregabalin›50mg / 1 capsule
Manufacturer / importer
Nexpharm Korea Co., Ltd.
Appearance
A hard capsule with an upper dark blue and a lower white part filled with white powder.
Packaging
30 capsules/bottle
Approval status
Expired

MFDS item code 202004146 · Approved 2020.05.31

This product's status changed to Expired on 2025.05.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medication is administered orally as pregabalin in two divided doses per day, regardless of food. Because this medication is primarily excreted by the kidneys, the dose must be adjusted in patients with impaired renal function. (See “5. Patients with renal impairment.”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of treatment.”) 2. Epilepsy Adults: The initial dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose for fibromyalgia is 300 mg–450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Although clinical studies have also been conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to a dose administered once as an additional dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended because data on safety and efficacy are insufficient. Adolescents aged 12–17 years: Use is not recommended because data on safety and efficacy are insufficient.

Ingredients

Manufacturer
Nexpharm Korea Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in patients with epilepsy, whether or not they have secondary generalized symptoms. Furthermore, it is effective in alleviating the symptoms of fibromyalgia. In other words, this drug helps improve the pain and seizure symptoms associated with various neurological disorders.

How to take

Adult dose

This medication is administered orally as pregabalin in two divided doses per day, regardless of food. Because this medication is primarily excreted by the kidneys, the dose must be adjusted in patients with impaired renal function. (See “5. Patients with renal impairment.”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of treatment.”) 2. Epilepsy Adults: The initial dose is 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose for fibromyalgia is 300 mg–450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Although clinical studies have also been conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to a dose administered once as an additional dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended because data on safety and efficacy are insufficient. Adolescents aged 12–17 years: Use is not recommended because data on safety and efficacy are insufficient.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if mood changes or symptoms of depression occur during treatment, you should inform your doctor immediately. This medication should not be used by patients with an allergy to its components or those with a genetic intolerance to lactose. Diabetic patients may need to adjust their blood sugar control medications due to weight gain following the use of this drug. If symptoms of angioedema occur, the medication should be stopped immediately, and elderly patients should be cautious of injuries due to dizziness or drowsiness. This medication may cause blurred vision or changes in eyesight, so consult a doctor if symptoms occur. If the medication is suddenly discontinued, withdrawal symptoms such as insomnia, headache, and anxiety may occur, so it should be tapered off gradually as instructed by a physician. Patients with a history of substance abuse should use this medication carefully due to the potential for misuse or dependence. Patients with impaired kidney function should adjust their dosage of this medication, and those with heart disease should also exercise caution. When used in conjunction with other drugs that have central nervous system depressant effects, there is a risk of respiratory depression, so be cautious when combining medications. During early pregnancy, it may affect the fetus, so it is advisable for pregnant women not to use it, and women of childbearing age should use effective contraception. Breastfeeding women should either discontinue breastfeeding or consult a physician since this medication may be passed into breast milk. Before driving or operating dangerous machinery, confirm whether this medication causes dizziness or drowsiness, and avoid such activities if symptoms are present. In cases of overdose, symptoms like confusion, drowsiness, and depression may occur, so immediate medical attention should be sought for appropriate treatment. Keep out of reach of children and be careful not to transfer the medication to another container.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 203 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • melancholy
  • thoughts of suicide
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • major congenital malformations
  • nasopharyngitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual dysfunction
  • agitation
  • mood swings
  • emotional lability
  • emotional dullness
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to restrain
  • apathy
  • ataxia
  • motor coordination issues
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonus
  • reduced reflexes
  • movement disorders
  • psychomotor agitation
  • position-induced dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • taste loss
  • writing difficulties
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field loss
  • photophobia
  • dry eyes
  • eye swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear secretion
  • eye irritation
  • mydriasis
  • vibration
  • changes in depth perception of vision
  • strabismus
  • brightness of vision
  • dizziness
  • auditory hyperesthesia
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • hives
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • pain in limbs
  • cervical spasm
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disturbances
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • breast hypertrophy
  • peripheral edema
  • swelling
  • gait abnormalities
  • falls
  • feeling drunk
  • sensation abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • exacerbation of convulsions
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. Additionally, it is advisable to keep it at room temperature between 15°C and 30°C, avoiding direct sunlight.

Appearance and packaging

Appearance

A hard capsule with an upper dark blue and a lower white part filled with white powder.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.